The American Society of Addiction Medicine (ASAM) has developed and released the National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use to provide information on evidence-based treatment of opioid use disorder. This guideline is the first to address all the FDA-approved medications available to treat addiction involving opioid use and opioid overdose - methadone, buprenorphine, naltrexone and naloxone - in a single document. The guideline is intended to help clinicians make evidence-based clinical decisions when prescribing pharmacotherapies to patients with opioid use disorder, and includes specific recommendations for special populations, including adolescents, pregnant women, individuals with pain, individuals with co-occuring psychiatric disorders and individuals in the criminal justice system.
For more clinical guidance on MAT, see SAMHSA’s Treatment Improvement Protocol on Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs and Medication for the Treatment of Alcohol Use Disorder: A Brief Guide. SAMHSA also funds the Providers’ Clinical Support System for Medication Assisted Treatment to educate and train providers.